2019
Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*
Foss FM, Parker TL, Girardi M, Li A. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*. Leukemia & Lymphoma 2019, 60: 2927-2930. PMID: 31119966, DOI: 10.1080/10428194.2019.1612061.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaIncidence of mucositisAddition of leucovorinSkin reactionsLeucovorin administrationMucositis incidenceMucositis occurrenceDisease stabilizationAdverse eventsClinical responseCTCL patientsPoor prognosisLeucovorinMucositisPatientsResponse rateLymphomaPralatrexateIncidenceEfficacyPrognosisDosingAdministration
2018
Skin Microbiota as Antigenic Triggers for Cutaneous T Cell Lymphoma
Dehner C, Ruff W, Foss F, Girardi M, Kriegel M. Skin Microbiota as Antigenic Triggers for Cutaneous T Cell Lymphoma. The Journal Of Immunology 2018, 200: 166.24-166.24. DOI: 10.4049/jimmunol.200.supp.166.24.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaT cellsSkin lesionsCell lymphomaPathogenesis of CTCLActive skin lesionsCutaneous T-cellChronic skin lesionsAdaptive immune responsesPatient T cellsSLE patientsCTCL patientsAntigenic triggerLesional skinRRNA sequencingAntigenic challengeMALT lymphomaHealthy donorsImmune responseAntigenic driversSkin commensalsPatient biopsiesClonal proliferationV1-3
2012
Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma
Parker T, Barbarotta L, Girardi M, Foss F. Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma. Blood 2012, 120: 3660. DOI: 10.1182/blood.v120.21.3660.3660.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaRefractory cutaneous T-cell lymphomaRefractory peripheral T-cell lymphomaCutaneous toxicityMajority of patientsAdverse eventsMedian ageSkin flareMedian numberLow doseDiagnosis of PTCLCommon adverse eventsSpeakers bureauOff-label useIntravenous antibioticsCTCL patientsFirst doseToxic erythemaDose escalationCTCL lesionsMoist desquamationRetrospective reviewSkin breakdown
2011
Characterization of the DNA Copy-Number Genome in the Blood of Cutaneous T-Cell Lymphoma Patients
Lin WM, Lewis JM, Filler RB, Modi BG, Carlson KR, Reddy S, Thornberg A, Saksena G, Umlauf S, Oberholzer PA, Karpova M, Getz G, Mane S, Garraway LA, Dummer R, Berger CL, Edelson RL, Girardi M. Characterization of the DNA Copy-Number Genome in the Blood of Cutaneous T-Cell Lymphoma Patients. Journal Of Investigative Dermatology 2011, 132: 188-197. PMID: 21881587, PMCID: PMC3841973, DOI: 10.1038/jid.2011.254.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaBlood involvementLeukemic cutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsT-cell lymphoma patientsNormal CD4 countPeripheral blood isolatesT-cell lymphomaCTCL cell linesPotential future therapeutic developmentsT-cell malignanciesFuture therapeutic developmentSignificant copy number alterationsCD4 countSpectrum of stagesCTCL patientsSézary syndromeLymph nodesLymphoma patientsHodgkin's lymphomaPeripheral bloodBlood isolatesCutaneous patchCTCL samplesPatientsHigh-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade
Kießling M, Oberholzer PA, Mondal C, Karpova MB, Zipser MC, Lin WM, Girardi M, MacConaill LE, Kehoe SM, Hatton C, French LE, Garraway LA, Polier G, Süss D, Klemke CD, Krammer PH, Gülow K, Dummer R. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood 2011, 117: 2433-2440. PMID: 21209378, PMCID: PMC3952811, DOI: 10.1182/blood-2010-09-305128.Peer-Reviewed Original ResearchMeSH KeywordsBiopsyHigh-Throughput Screening AssaysHumansLymphoma, T-Cell, CutaneousMitogen-Activated Protein Kinase KinasesMutationMycosis FungoidesNeoplasm StagingProtein Kinase InhibitorsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)raf Kinasesras ProteinsSezary SyndromeSignal TransductionConceptsCutaneous T-cell lymphomaStage IV patientsHUT78 cellsIV patientsPleomorphic cutaneous T-cell lymphomaHigh-throughput mutation profilingMEK inhibitorsCTCL cell line Hut78T-cell lymphomaRAS/RAF/MEKCTCL cell linesOncogenic mutationsCommon oncogenic mutationsCTCL patientsOverall survivalSézary syndromeMycosis fungoidesBiopsy specimensPatients profitPreclinical resultsMEK inhibitor U0126NRAS mutationsLymphoid cellsCTCL samplesRas mutations
2006
Transimmunization for cutaneous T cell lymphoma: A phase I study
Girardi M, Berger CL, Wilson LD, Christensen IR, Thompson KR, Glusac EJ, Edelson RL. Transimmunization for cutaneous T cell lymphoma: A phase I study. Leukemia & Lymphoma 2006, 47: 1495-1503. PMID: 16966259, DOI: 10.1080/10428190600581419.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaCTCL patientsCell lymphomaMalignant cellsCD8 T cell poolPhase I clinical studyT cell poolSignificant mean reductionElectron beam therapyInfiltrative lesionsClinical studiesDendritic antigenBlood monocytesTransimmunizationMean reductionTumor loadingPatientsMonoclonal antibodiesMalignant leukocytesMinimal toxicityBeam therapyPhase ICell poolVivo contact
1998
Tumor‐specific peptides in cutaneous T‐cell lymphoma: Association with class I major histocompatibility complex and possible derivation from the clonotypic T‐cell receptor
Berger C, Longley B, Imaeda S, Christensen I, Heald P, Edelson R. Tumor‐specific peptides in cutaneous T‐cell lymphoma: Association with class I major histocompatibility complex and possible derivation from the clonotypic T‐cell receptor. International Journal Of Cancer 1998, 76: 304-311. PMID: 9579563, DOI: 10.1002/(sici)1097-0215(19980504)76:3<304::aid-ijc3>3.0.co;2-z.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAntigens, NeoplasmCD8-Positive T-LymphocytesGenes, T-Cell Receptor betaHistocompatibility Antigens Class IHumansLymphoma, T-Cell, CutaneousMolecular Sequence DataPeptidesProtein ConformationSequence AlignmentSequence Homology, Amino AcidSkin NeoplasmsT-Lymphocyte SubsetsT-Lymphocytes, CytotoxicTumor Necrosis Factor-alphaConceptsCutaneous T-cell lymphomaT cell receptorClonotypic T cell receptorIdiotypic peptideT-cell lymphomaCD8 cellsClass I moleculesCTCL patientsClass I peptidesTumor cellsClass II moleculesAnti-tumor vaccinesClass I major histocompatibilityMalignant T cellsCTCL tumor cellsTumor-specific peptidesI peptidesTNF-alpha assayCD8 responsesNovel class IPeptide-binding motifTumor necrosisT cellsCTCL cells
1995
Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy
Wilson L, Licata A, Braverman I, Edelson R, Heald P, Feldman A, Kacinski B. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. International Journal Of Radiation Oncology • Biology • Physics 1995, 32: 987-995. PMID: 7607973, DOI: 10.1016/0360-3016(95)00073-8.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyDoxorubicin/cyclophosphamideCutaneous T-cell lymphoma patientsAdjuvant doxorubicin/cyclophosphamideT-cell lymphoma patientsExtracorporeal photochemotherapyComplete responseOverall survivalAdjuvant therapyElectron beam therapyAdjuvant regimenFree survivalCTCL patientsLymphoma patientsBeam therapyAddition of chemotherapyAdvanced stage CTCLClinical complete responseSystemic adjuvant therapyGood partial responseSignificant survival benefitBetter overall survivalRelapse-free survivalSoles of feetNontoxic regimen
1994
Novel prognostic factors predictive of prolonged relapse-free and overall survival in advanced stage CTCL (mycosis fungoides) patients treated with total skin electron beam therapy
Kacinski B, Wilson L, Quiros P, Kolenik S, Heald P, Edelson R, Braverman I. Novel prognostic factors predictive of prolonged relapse-free and overall survival in advanced stage CTCL (mycosis fungoides) patients treated with total skin electron beam therapy. International Journal Of Radiation Oncology • Biology • Physics 1994, 30: 268. DOI: 10.1016/0360-3016(94)90823-0.Peer-Reviewed Original Research
1992
The role of novel prognostic factors & adjuvant therapy in CTCL (Mycosis fungoides) patients treated with total skin electron beam therapy
Kacinski B, Murren J, Friedman N, Braverman I, Cooper D. The role of novel prognostic factors & adjuvant therapy in CTCL (Mycosis fungoides) patients treated with total skin electron beam therapy. International Journal Of Radiation Oncology • Biology • Physics 1992, 24: 229. DOI: 10.1016/0360-3016(92)90308-5.Peer-Reviewed Original Research
1991
Repeat courses of either total skin electron beam therapy (TSEBT) or local RT are safe and effective palliation to relapsed CTCL patients whose symptoms are not controlled by other topical or systemic anti-ctcl therapies
Kacinski B, Friedrtan N, Murren J, Cooper D, Braverman I. Repeat courses of either total skin electron beam therapy (TSEBT) or local RT are safe and effective palliation to relapsed CTCL patients whose symptoms are not controlled by other topical or systemic anti-ctcl therapies. International Journal Of Radiation Oncology • Biology • Physics 1991, 21: 212. DOI: 10.1016/0360-3016(91)90608-7.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply